Clinical Trial Update: A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial results compare two doses of CP-690,550 (tofacitinib) and the active comparator adalimumab (Humira) against placebo in rheumatoid arthritis; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Humira (adalimumab)
• Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2013-01-09